Vemurafenib

(Zelboraf®)

Zelboraf®

Drug updated on 11/15/2023

Dosage FormTablet (oral; 240mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
  • For the treatment of patients with Erdheim Chester Disease with BRAF V600 mutation.

Product Monograph / Prescribing Information

Document TitleYearSource
Zelboraf (vemurafenib) Prescribing Information.2020Genentech USA, Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.2023European Journal of Cancer
Vemurafenib in the treatment of erdheim chester disease: a systematic review.2022Cureus
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.2022Cancer treatment Reviews
Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis.2022Frontiers in Oncology
Adjuvant therapy of high-risk (Stages IIC-IV) malignant melanoma in the post interferon-alpha era: a systematic review and meta-analysis.2021Frontiers in Oncology
[Report in French] ZELBORAF® (vemurafenib) en monothérapie dans le traitement du mélanome non résécable ou métastatique à mutation BRAF V6002021Instance Nationale de l’Évaluation et de l’Accréditation en Santé (INEAS)
Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs).2021Journal of the European Academy of Dermatology and Venereology
Economic evaluation of systemic treatments for advanced melanoma: a systematic review.2020Value in Health
Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma.2019Clinical and Experimental Dermatology
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.2019European Journal of Cancer
Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF inhibitors: a systematic review.2019Cancers
Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies.2019European Academy of Dermatology and Venereology
Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis.2019JAMA
Efficacy and safety of dabrafenib–trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF-V600 mutation: a systematic review and network meta-analysis.2019Dermatologic Therapy
Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma.2019Clinical and Experimental Dermatology

Clinical Practice Guidelines